Henry E. Mark

Barcelona Institute for Global Health — Spain

Medicine · Health Sciences

18h-index2.0kcitations40works12.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(24), Liver Disease and Transplantation(9), Diet, Metabolism, and Disease(8), Child Nutrition and Water Access(7), Food Security and Health in Diverse Populations(7)

Publications39 total

A call to action from the Global Think-tank on Steatotic Liver Disease
Nature Health·2026
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
JAMA Network Open·2025· 2 citedOpen Access
Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries
Clinical Gastroenterology and Hepatology·2025· 2 cited
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
The Lancet Regional Health - Europe·2025· 9 citedOpen Access
WED-430 Best buys to diagnose and treat metabolic dysfunction-associated steatohepatitis among people living with diabetes type 2: a multicountry generalized cost-effectiveness analysis
Journal of Hepatology·2025
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Hepatology Communications·2025· 5 citedOpen Access
Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
Gastroenterology·2025· 66 citedOpen Access
2764 Optimising blood sugar monitoring in frail diabetic inpatients
Age and Ageing·2025
Mpox: Neglect has led to a more dangerous virus now spreading across borders, harming and killing people. Leaders must take action to stop mpox now
PLOS Global Public Health·2024· 1 citedOpen Access
S1931 The Utilization of Non-Invasive Tests (NITs) for the Clinical Management of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the United States
The American Journal of Gastroenterology·2024
Best buy interventions to address the burden of steatotic liver disease
˜The œLancet. Gastroenterology & hepatology·2024· 13 cited
Political courage needed to prevent the next pandemic
The Lancet·2024· 2 cited
WED-248 A four-country modelling study on doubling MASH diagnostic rates by 2027
Journal of Hepatology·2024
FRI-218 Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States
Journal of Hepatology·2024· 4 cited
Opportunities and challenges following approval of resmetirom for MASH liver disease
Nature Medicine·2024· 52 citedOpen Access
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Hepatology Communications·2024· 37 citedOpen Access
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Journal of Hepatology·2023· 30 citedOpen Access
A global action agenda for turning the tide on fatty liver disease
Hepatology·2023· 74 citedOpen Access
A global research priority agenda to advance public health responses to fatty liver disease
Journal of Hepatology·2023· 119 citedOpen Access
A global research priority agenda to advance public health responses to fatty liver disease
Journal of Hepatology·2023· 5 cited
page 1 of 2Next →

Frequent Co-authors

Jeffrey V. Lazarus(25), Alina M. Allen(17), Jörn M. Schattenberg(16), Zobair M. Younossi(16), Emmanuel Tsochatzis(12), Vincent Wai‐Sun Wong(12), Hannes Hagström(11), Shira Zelber‐Sagi(11), Kenneth Cusi(10), Mary E. Rinella(9), C Wendy Spearman(9), Laurent Castéra(8), Manuel Romero‐Gómez(8), Saleh A. Alqahtani(8), Frank Tacke(8), Luca Valenti(7), Patrizia Burra(7), Ajay Duseja(7), Marcela Villota‐Rivas(7), Naim Alkhouri(7)